These controversial data may be due to the heterogeneous MM therapies based on the combination of two or more drugs with immunosuppressive effects that further affect hypogammaglobulinemia, concealing the efficacy of therapeutic Igs, and/or to the lack of large and homogeneous studies based on personal clinicians’ experience. This evidence concerns the gene CUBN and Miyoshi myopathy.